Accelerated Immunotherapy Schedules and Premedication

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 251-263

  Calabria, Christopher W ^a   Cox, Linda ^b  

^a ENTAA Care and PA   (United States)

^b NONE   (United States)

Author keywords

Accelerated immunotherapy; Premedication; Schedule; Subcutaneous immunotherapy

Indexed keywords

ALUTARD; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CORTICOSTEROID; DIMETINDENE; FEXOFENADINE; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INTERLEUKIN 10; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; METHYLPREDNISOLONE; MONTELUKAST; OMALIZUMAB; PLACEBO; POLLEN ANTIGEN; PREDNISONE; RANITIDINE; TERFENADINE; THEOPHYLLINE; ZAFIRLUKAST;

ABDOMINAL CRAMP; ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGY; ALTERNARIA ALTERNATA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONJUNCTIVA DISEASE; CONSCIOUSNESS DISORDER; COUGHING; DERMATOPHAGOIDES; DESENSITIZATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPIPHORA; ERYTHEMA; FORCED EXPIRATORY VOLUME; HEAT SENSATION; HOT FLUSH; HOUSE DUST ALLERGY; HUMAN; HYMENOPTERA; HYPOTENSION; IMMUNOTHERAPY; LARYNX EDEMA; MAINTENANCE DRUG DOSE; MOULD; MOUTH DISEASE; NAUSEA; NOSE CONGESTION; POLLEN ALLERGY; PREMEDICATION; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINORRHEA; SIDE EFFECT; SKIN TEST; SNEEZING; STRIDOR; TASTE DISORDER; THROAT DISEASE; TONGUE EDEMA; URTICARIA; UTERUS DISEASE; VOMITING; WHEEZING;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; PREMEDICATION;

EID: 79955448866     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.02.001     Document Type: Review

References (53)

1. Nanda A., O'Connor M., Anand M., et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004, 114:1339-1344.
2. Tabar A.I., Echechipia S., Garcia B.E., et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005, 116:109-118.
3. Francis J.N., James L.K., Paraskevopoulos G., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121:1120-1125.
4. Serrano P., Justicia J.L., Sanchez C., et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol 2009, 102:247-252.
5. Zhang L., Wang C., Han D., et al. Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009, 148:161-169.
6. Martinez-Canavate A., Eseverri J.L., Rodenas R., et al. Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. A multicentre study. Allergol Immunopathol (Madr) 2005, 33(3):138-141.
7. Nielsen L., Johnsen C.R., Mosbech H., et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996, 97:1207-1213.
8. Winther L., Malling H.J., Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis, II: side-effects. Allergy 2000, 55:327-335.
9. Mellerup M.T., Hahn G.W., Poulsen L.K., et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000, 30:1423-1429.
10. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006, 97:126-138.
11. Stewart G.E., Lockey R.F. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992, 90:567-578.
12. Parmiani S., Fernandez Tavora L., Moreno C., et al. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol (Madr) 2002, 30(5):283-291.
13. Walker S.M., Pajno G.B., Lima M.T., et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001, 107:87-93.
14. Harvey S.M. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004, 92:414-419.
15. Portnoy J., Bagstad K., Kanarek H., et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy Asthma Immunol 1994, 73:409-418.
16. Bernstein J.A., Kagen S.L., Bernstein D.I., et al. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994, 73:423-428.
17. Roll A., Hofbauer G., Ballmer-Weber B.K., et al. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006, 16:79-85.
18. Goldberg A., Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003, 91:405-410.
19. Schiavino D., Nucera E., Pollastrini E., et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004, 92:409-413.
20. Tankersley M.S., Walker R.L., Butler W.K., et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002, 109:556-562.
21. Dietrich J.J., Moore L.M., Nguyen S., et al. Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication. Ann Allergy Asthma Immunol 2009, 103:535-536.
22. Bousquet J., Hejjaoui A., Dhivert H., et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989, 83:797-802.
23. Heijaioui A., Ferrando R., Dhivert H., et al. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992, 89:925-933.
24. Armentia-Medina A., Blanco-Quiros A., Martin-Santos J.M., et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy Asthma Immunol 1989, 63:127-135.
25. Bousquet J., Braquemond P., Feinberg J., et al. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy Asthma Immunol 1986, 56:456-459.
26. Bousquet J., Hejjaoui A., Skassa-Brociek W., et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, I: rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987, 80:591-598.
27. Moverare R., Vesterinen E., Metso T., et al. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol 2001, 86:337-342.
28. Casale T.B., Busse W.W., Kline J.N., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117:134-140.
29. Bousquet J., Becker W.M., Hejjaoui A., et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species, II: efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991, 88:43-53.
30. Bousquet J., Maasch H.J., Hejjaoui A., et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, III: efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989, 84:546-556.
31. Bousquet J., Guerin B., Dotte A., et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy 1985, 15:179-193.
32. Dolz I., Martinez-Cocera C., Bartolome J.M., et al. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996, 51:489-500.
33. Horst M., Hejjaoui A., Horst V., et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990, 85:460-472.
34. Hedlin G., Graff-Lonnevig V., Heilborn H., et al. Immunotherapy with cat- and dog-dander extracts, V: effects of 3 years of treatment. J Allergy Clin Immunol 1991, 87:955-964.
35. Hedlin G., Braff-Lonnevig V., Heilborn H., et al. Immunotherapy with cat- and dog-dander extracts, II: in vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986, 77:488-496.
36. Hedlin G., Heilborn H., Lilja G., et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995, 96:879-885.
37. Lilja G., Sundin B., Graff-Lonnevig V., et al. Immunotherapy with cat- and dog-dander extracts, IV: effects of 2 years of treatment. J Allergy Clin Immunol 1989, 83:37-44.
38. Portnoy J., King K., Kanarek H., et al. Incidence of systemic reactions during rush immunotherapy. Ann Allergy Asthma Immunol 1992, 68:493-498.
39. Sharkey P., Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol 1996, 76:175-180.
40. Sturm G., Kranke B., Rudolph C., et al. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002, 110:928-933.
41. Massanari M., Nelson H., Casale T., et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010, 125:383-389.
42. Ohashi Y., Nakai Y., Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:600-605.
43. Reimers A., Hari Y., Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000, 55:484-488.
44. Brockow K., Kiehn M., Riethmuller C., et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997, 100:458-463.
45. Berchtold E., Maibach R., Muller U. Reduction of side effect from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992, 22:59-65.
46. Muller U., Hari Y., Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001, 107:81-86.
47. Muller U., Jutel M., Reimers A., et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008, 122:1001-1007.
48. Ewbank P.A., Murray J., Sanders K., et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003, 111:155-161.
49. Wohrl S., Gamper S., Hemmer W., et al. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007, 144:137-142.
50. Heijaioui A., Dhivert H., Michel F.B., et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990, 85:473-479.
51. Kopp M.V., Brauburger J., Riedinger F., et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 110:728-735.
52. Kuehr J., Brauburger J., Zielen S., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274-280.
53. Cox L., Larenas-Linnemann D., Lockey R.F., et al. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010, 125:569-574.